Barinthus Biotherapeutics (BRNS) Institutional Ownership $0.65 -0.16 (-19.26%) Closing price 03:59 PM EasternExtended Trading$0.65 0.00 (-0.15%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Barinthus Biotherapeutics (NASDAQ:BRNS)CurrentInstitutional OwnershipPercentage25.20%Number ofInstitutional Buyers(last 12 months)6TotalInstitutional Inflows(last 12 months)$10.24MNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$243.66K Get BRNS Insider Trade Alerts Want to know when executives and insiders are buying or selling Barinthus Biotherapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data BRNS Institutional Buying and Selling by Quarter Barinthus Biotherapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/13/2025 Gilead Sciences Inc.369,855$360K0.0%-40.4%0.917% 5/13/2025 HighTower Advisors LLC37,450$36K0.0%N/A0.093% 2/14/2025 Gilead Sciences Inc.620,351$749K0.0%N/A1.542% 8/2/2024 Alphabet Inc.1,513,644$2.12M0.1%N/A3.878% 7/24/2024 Catalina Capital Group LLC17,819$25K0.0%N/A0.046% 7/16/2024 Ipswich Investment Management Co. Inc.23,075$32K0.0%N/A0.059% 7/16/2024 M&G Plc5,197,349$7.28M0.0%N/A13.316% 5/16/2024 BlueCrest Capital Management Ltd542,673$1.29M0.1%N/A1.394% 5/14/2024 DC Funds LP642,204$1.53M14.8%N/A1.650% (Data available from 1/1/2016 forward) BRNS Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of BRNS shares? During the previous two years, the following institutional investors and hedge funds held shares of Barinthus Biotherapeutics shares: M&G Plc ($7.28M), Alphabet Inc. ($2.12M), DC Funds LP ($1.53M), BlueCrest Capital Management Ltd ($1.29M), Gilead Sciences Inc. ($360K), HighTower Advisors LLC ($36K), and Ipswich Investment Management Co. Inc. ($32K).Learn more on BRNS's institutional investors. What percentage of Barinthus Biotherapeutics stock is owned by institutional investors? 25.20% of Barinthus Biotherapeutics stock is owned by institutional investors. Learn more on BRNS's institutional investor holdings. Which institutional investors have been buying Barinthus Biotherapeutics stock? The following institutional investors have purchased Barinthus Biotherapeutics stock in the last 24 months: M&G Plc ($5.20M), Alphabet Inc. ($1.51M), DC Funds LP ($642.20K), Gilead Sciences Inc. ($620.35K), BlueCrest Capital Management Ltd ($542.67K), HighTower Advisors LLC ($37.45K), and Ipswich Investment Management Co. Inc. ($23.08K). How much institutional buying is happening at Barinthus Biotherapeutics? Institutional investors have bought a total of 8,594,565 shares in the last 24 months. This purchase volume represents approximately $13.06M in transactions. Which Barinthus Biotherapeutics major shareholders have been selling company stock? The following institutional investors have sold Barinthus Biotherapeutics stock in the last 24 months: Gilead Sciences Inc. ($250.50K). How much institutional selling is happening at Barinthus Biotherapeutics? Institutional investors have sold a total of 250,496 shares in the last 24 months. This volume of shares sold represents approximately $243.66K in transactions. Related Companies IKT Institutional Ownership ALEC Institutional Ownership GLSI Institutional Ownership EDIT Institutional Ownership EPRX Institutional Ownership TARA Institutional Ownership PLX Institutional Ownership FTLF Institutional Ownership LRMR Institutional Ownership NKTX Institutional Ownership This page (NASDAQ:BRNS) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.